Everolimus

BIOMEDE: comparing 3 targeted therapies + radiotherapy from ITCC, SIOPE-Brain and ANZCHOG 1:32
BIOMEDE: comparing 3 targeted therapies + radiotherapy from ITCC, SIOPE-Brain and ANZCHOG
Jacques Grill • 3 Jun 2023
Key trials to determine treatment of advanced pancreatic NETs 7:09
Key trials to determine treatment of advanced pancreatic NETs
Rocio Garcia-Carbonero • 17 Mar 2023
Highlights in renal cell carcinoma from ASCO GU 2023 and what to look out for in the future 1:44
Highlights in renal cell carcinoma from ASCO GU 2023 and what to look out for in the future
Thomas Powles • 23 Feb 2023
Post-second-line systemic treatment for advanced RCC 1:02
Post-second-line systemic treatment for advanced RCC
Tian Zhang • 17 Feb 2023
Unanswered questions in gastrointestinal neuroendocrine tumors 1:54
Unanswered questions in gastrointestinal neuroendocrine tumors
Bahar Laderian • 19 Jan 2023
SWOG S1207: adjuvant ET +1 yr everolimus shows benefit in premenopausal high-risk HR+/HER2- BC 1:59
SWOG S1207: adjuvant ET +1 yr everolimus shows benefit in premenopausal high-risk HR+/HER2- BC
Lajos Pusztai • 8 Dec 2022
What does the future hold for SERDs in ER+ breast cancer? 2:35
What does the future hold for SERDs in ER+ breast cancer?
Sara Tolaney • 13 Sep 2022
Therapeutic strategies to maximize sensitivity to endocrine therapy in breast cancer 1:00
Therapeutic strategies to maximize sensitivity to endocrine therapy in breast cancer
Erika Hamilton • 12 Sep 2022
GU cancer updates from ASCO 2022 0:53
GU cancer updates from ASCO 2022
Scott Tagawa • 3 Jun 2022
AMEERA-1 updates: amcenestrant plus palbociclib for patients with ER+/HER2– advanced breast cancer 4:40
AMEERA-1 updates: amcenestrant plus palbociclib for patients with ER+/HER2– advanced breast cancer
Mario Campone • 30 Sep 2021
Current treatment options for patients with NETs 2:03
Current treatment options for patients with NETs
Jonathan Strosberg • 7 Jun 2021
Ribociclib plus everolimus in advanced dedifferentiated liposarcoma 3:25
Ribociclib plus everolimus in advanced dedifferentiated liposarcoma
Margaret von Mehren • 26 May 2021
VEGFR inhibitors with immune checkpoint inhibitors for advanced renal cancer 4:44
VEGFR inhibitors with immune checkpoint inhibitors for advanced renal cancer
Tian Zhang • 17 Feb 2021
Highlights in kidney and bladder cancer at ASCO GU 2021 4:45
Highlights in kidney and bladder cancer at ASCO GU 2021
Petros Grivas • 14 Feb 2021
Current treatment landscape for kidney cancer 5:11
Current treatment landscape for kidney cancer
Robert Jones • 15 Feb 2021
Updates in the use of neratinib in fibrolamellar carcinoma and biliary tract cancer 2:21
Updates in the use of neratinib in fibrolamellar carcinoma and biliary tract cancer
Ghassan Abou-Alfa • 21 Jan 2021

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals